Development and evaluation of enzyme-linked immunosorbent assay of nucleic acid sequence-based amplification for diagnosis of invasive aspergillosis

Li Du¹, Yun Xia¹*, Yunyan He², Qingquan Pu¹, Ruoyi Hua¹ and Wenyao Wu¹

Abstract
Invasive aspergillosis (IA) is a life-threatening infection in immunocompromised patients, rapid and sensitive detection of *Aspergillus* from clinical samples has been a major challenge in the early diagnosis of IA. An enzyme-linked immunosorbent assay of nucleic acid sequence-based amplification (NASBA-ELISA) was developed to fulfill the need for the efficient diagnosis of these infections. The primers targeting 18S rRNA were selected for the amplification of *Aspergillus* RNA by the isothermal digoxigenin (DIG)-labeling NASBA process. The DIG-labeled RNA amplicons were hybridized with a specific biotinylated DNA probe immobilized on streptavidin-coated microtiter plate. The hybrids were colorimetrically detected by the addition of an anti-DIG antibodies linked to ALP and substrate (disodium 4-nitrophenyl phosphate). The detection limit of the *Aspergillus* NASBA-ELISA system was 1 CFU and the RNA in non-target bacteria or fungus was not amplified. The performance of this NASBA-ELISA compared to RT-PCR and galactomannan (GM) was evaluated by testing blood samples from 86 patients at high risk for IA. The sensitivity of NASBA-ELISA, RT-PCR and GM-ELISA was 80.56 % (95 % CI 63.98–91.81), 72.22 % (95 % CI 54.81–85.80), 58.33 % (95 % CI 40.76–74.49), respectively, and the specificity was 80.00 % (95 % CI 66.28–89.97), 84.00 % (95 % CI 70.89–92.83), 82.00 % (95 % CI 68.56–91.42). The efficiency of the three methods in various combinations was also evaluated. Combination of NASBA-ELISA and GM-ELISA testing achieved perfect specificity (100 %; 95 % CI 92.89–100) and perfect positive predictive value (100 %; 95 % CI 83.16–100). The best sensitivity (97.22 %; 95 % CI 85.47–99.93) and the highest Youden index (0.652) were obtained by testing with both NASBA and RT-PCR in parallel. In conclusion, the NASBA-ELISA assay consists of an alternative process for large-scale samples detection with semi-quantitative results and provides good clinical performance without resorting to expensive equipment. This assay makes it possible for the NASBA based RNA diagnosis to become a routine work in laboratories in less developed countries with fewer resources.

Keywords: NASBA-ELISA, RT-PCR, GM-EIA, Invasive aspergillosis

Introduction
Invasive aspergillosis (IA), an opportunistic fungal infection, is increasingly recognized as a major cause of morbidity and mortality in immunocompromised patients, including those receiving aggressive chemotherapy or immunosuppressive drugs (Chandrasekar 2010; Barton 2013; Leventakos et al. 2010). Because of its high mortality, early diagnosis is the key to successful treatment. However, microbiological examination such as *Aspergillus* culture is time-consuming and has lower positive rate (Torelli et al. 2011), it is also difficult in distinguishing between infection and colonization. Diagnosis by biopsy or histopathology is difficult due to the severity of illness in these patients. Galactomannan by enzyme immunosorbent assay (GM-EIA) is one of the standard measures (Yoo et al. 2007;
Boutboul et al. 2002) and is included as an important component of microbiological factors in the diagnostic criteria devised by the Mycology Study Group of the European Organization for Research and Treatment of Cancer (EORTC/MSG) (De Pauw et al. 2008). Performance of GM-EIA can vary considerably and has been shown to be affected by various factors, leading to both false positive and false-negative results (Mikulksa et al. 2012). Galactomannan is not unique to Aspergillus spp., there are cross-reacting antigens in other fungus and some antibiotic agents. Antibody detection methods often cannot distinguish between current and past infection and it performs poorly in patients with haematological malignancy or having undergone bone marrow or stem cell transplantation.

More recently, nucleic acid amplification tests (NAATs) in vitro can provide increased sensitivity and specificity of detection (van der Vliet et al. 1993; Ieven and Goossens 1997). Nucleic acid sequence-based amplification (NASBA) is a molecular method for amplification of target RNA segments in which the necessity of thermo cycling is excluded due to lack of any thermal variation in the reaction environment. The amplification efficiency of NASBA is more robust than that of PCR (Mercier-Delarue et al. 2014), yielding more than $10^{12}$ amplicons in as little as 30 min (Zhao et al. 2009). The advantages of NASBA have promoted interest in evaluating its application to detection of Aspergillus RNA in clinical samples. The main drawback of NASBA is that special care is needed in sample preparation and detection, due to the profound susceptibility of RNA to degradation. Thus, further studies are warranted to improve the ability to quantify pathogen load and develop automated, standardized protocols for sample processing and data analysis. Conventional NASBA requires several steps after RNA amplification, including electrophoresis or blotting and hybridization, which are inconvenient for detecting a large number of samples in clinical routine. The NASBA-enzyme-linked immunosorbent assay (NASBA-ELISA) consisting of an alternative process for large-scale screening allows for application in daily life. This technique combines an immunological method to quantify the NASBA product directly after immobilization of biotinylated DNA on a microplate. The NASBA-ELISA can be performed without special equipment and reagents for detection of amplified product compared to NASBA-electrophoresis. Therefore, NASBA-ELISA allows the using of RNA based diagnosis for routine purposes in poor developed laboratories.

The aim of this work was developing an NASBA-ELISA system as an improvement over traditional assays to detect Aspergillus 18s RNA in human blood samples for diagnosis of invasive aspergillosis. RT-PCR and GM test were performed simultaneously to evaluate the performance of the three methods.

**Materials and methods**

**Fungal and bacterial strains**

A. fumigatus strain CMCC A1a, kindly provided by Dr. WeiPing Lu (Daping Hospital, Third Military Medical University of People, Liberation Army, ChongQing, China), was grown on Sabouraud's dextrose agar at 37°C for 2–3 days. The number of Aspergillus spores diluted in saline suspension was quantified using a Neubauer chamber, and a solution containing approximately $10^5$ spores was used for total RNA extraction. Strains of E.coli ATCC25922, Candida albicans ATCC64548, Staphylococcus aureus ATCC29213, Pseudomonas aeruginosa ATCC27853 and Cryptococcus neoformans FY226 (isolated from clinical samples) were cultured on blood agar at 37°C for 1–2 days. The total RNA from these strains was extracted using Trizol reagent (Invitrogen, California, America) strictly following the manufacturer’s instruction.

**Patient populations and blood samples**

The definitions of invasive fungal infection according to the EORTC/MSG (De Pauw et al. 2008) updated criterion are classified into “proven”, “probable” and “possible”. To define as a proven invasive fungal infection it is required that a fungal hyphae or spores be detected by histological analysis or in the culture of a specimen obtained by a sterile procedure from a normally sterile and clinically or radiologically abnormal site consistent with an infectious disease process of tissue taken from the infected site of the disease. Probable invasive fungal infection requires the presence of a host factor, a clinical criterion, and symptoms consistent with the disease entity, and mycological evidence including: direct microscopic analysis, culture and serologic test such as GM.

Based on this criterion, a total of 36 patients at high risk for IA (including 9 proven cases, 27 probable cases) were served as test group and 50 patients not achieving an EORTC/MSG diagnosis criterion were served as control group. Cases were selected on the solid basis of sample availability and diagnosis, whereas controls were randomly selected from a period of testing similar to that of the IA cases. All patients were enrolled from January 2014 to December 2015 in the First Affiliated Hospital of Chongqing Medical University, a 3200-bed teaching hospital in Chongqing, southwestern China. Information of patients was retrieved from the hospital information system and the laboratory information system (Additional file 1). Plasma samples were collected from the samples that were sent to our department for (1,3)-β-D-glucan and galactomannan detection before any antifungal
therapy began. Plasma was separated from each fresh blood sample by centrifugation at 2500×g, transformed to Rnase free tubes and stored at −80 °C for further use.

**Aspergillus GM detection**

Platelia kits (Bio-Rad Laboratories, Hercules, CA) were used to measure the galactomannan level in blood samples. Assay performance and interpretation of positivity were performed by an investigator blinded to case status and as directed by the manufacturer. Optical densities were determined using a threshold index (optical density at 450/620 nm [OD450/620] of sample/OD450/620 of threshold control) with the Sunrise Microplate Reader (Tecan, Männedorf, Switzerland). Samples were run with positive, negative, and threshold controls supplied by the manufacturer. Optical density index was calculated as the optical density of the sample divided by the mean optical density of 2 threshold controls. On these grounds, any value above 0.5 was considered positive.

**RNA extraction**

In terms of determining analytical sensitivity the NASBA-ELISA assays, briefly, fungal spores suspensions of a certain concentration (10⁶/ml, 10⁵/ml, 10⁴/ml, 10³/ml) were prepared by microscope count method using Neubauer’s hemacytomete. 100 μL portions of fungal suspensions which had been grinded in mortar (free of Rnase) with liquid nitrogen were used for RNA extraction by total RNA rapid extraction kit. In terms of clinical application on the NASBA-ELISA, 200 μL of plasma samples (restored to room temperature from −80 °C) were used for RNA extraction by the same kit as above. The above samples mixed 300 μL of RLS lysis buffer followed by incubation for 10 min at room temperature. The tubes were vortexed vigorously for 15 s and then incubated for 3 min after addition of 150 μL chloroform. The aqueous phase was transferred to a spin column AC and mixed with 500 μL of 70 % ethanol, followed by centrifugation at 12,000×g for 10 min at 4 °C. The RNA was washed sequentially with buffer RE and buffer RW. Finally, 60 μL eluate was obtained and stored at −80 °C until further use. (Low concentration of RNA was obtained through tenfold serial dilutions of RNA extracted with high concentrations of spores).

**Primers and probe**

A primer pair encoding a highly conserved 18S rRNA region specific for the *Aspergillus* genus was chosen as previously reported to amplify a 243 nucleotide fragment of the target RNA that includes the species-specific region for oligonucleotide probe to identify the *Aspergillus* spp. (Loeffler et al. 2001). The reverse primer (Primers1.2) bears the bacteriophage T7 RNA polymerase promoter binding region and preferred transcriptional initiation sequence at its 5′ end. A biotinylated oligonucleotide probe (hybridization probe) corresponding to an internal region defined by the primers was synthesized for the detection of amplified target RNA (Table 1).

**Reverse transcriptase PCR (RT-PCR) process**

Reverse transcription was performed in an ABI Veriti™ 96-Well Thermal Cycler (Applied Biosystems; Life Technologies, Carlsbad, CA, USA) with a total reaction volume of 20 μL per well containing 4 μL 5× PrimeScript buffer, 1 μL PrimeScript Enzyme Mix × 1, 1 μL Oligo DT primer (50 μm), 1 μL random 6 mers (100 μm), 5 μL template RNA, 8 μL Rnase water. Thermal cycling conditions were 37 °C for 15 min, followed by 85 °C for 5 s and 4 °C for 5 s and the cDNA product was as template of PCR described below.

PCR reagents in a final volume of 25 μL included: 2 μL template cDNA, 12.5 μL Taq DNA polymerase (5 U/μL), 1 μL of each primer (10 pmol/μL, the same as NASBA primers), 3.5 μL dH2O. The PCR program was carried out at 95 °C for 10 min, followed by 35 cycles of 30 s at 95 °C and 30 s at 72 °C. The final extension was at 72 °C for 5 min. PCR products were electrophoresed in 1 % agarose followed by staining with Goldview then visualized under ultraviolet light, and the results were recorded by photography.

**Digoxigenin (DIG)-labeling NASBA process**

For DIG-labeling NASBA reaction, *Aspergillus* RNA sample (5 μL) was suspended in 10 μL of amplification reaction mixture (Table 1).

### Table 1 Nucleotide sequences of oligonucleotide primers and probe used in this study

| Primers/probe | Sequence (5’-3’) | Length (bp) |
|---------------|-----------------|-------------|
| Primers 2.1   | 5’-GCCGGCGGTATCCACGTCCAATA-3’ | 24 |
| Primers 1.2 + T7<sup>a</sup> | 5’-AATTCTAATACGACTACTATAGGGGAGCAAAGGCCTGCTTTGAACA-3’ | 47 |
| Hybridization probe | Bioth-GGTCCGCCTCACCGCGAGTACTG-3’ | 20 |
| NASBA product | | 243 |

<sup>a</sup> Underlining indicates the T7 promoter region
reagent solution containing 2 mmol/L each NTP, 0.2 mmol/L Digoxigenin-11-UTP, 1.6 mmol/L each dNTP, 40 mmol/L Tris–HCl (pH 8.5), 70 mmol/L KCl, 5 mmol/L dithiothreitol, 12 mmol/L MgCl₂, 0.375 mol/L sorbitol, 12 U ribonuclease inhibitor (Promega, Fitchburg, WI, USA), 0.4 μmol/L each primer, followed by an incubation at 65 °C for 5 min and at 41 °C for another 5 min. Then, 5 μL enzyme mixture (40U T7 RNA polymerase (Promega), 2.0 μg bovine serum albumin, 8U avian myeloblastosis virus reverse transcriptase (Takara Bio), and 0.1 U RNase H) was added. The reaction mixture was incubated for 90 min at 41 °C for isothermal amplification. Negative controls consisted of all of the same reagents but substituting for the target with an equal volume of buffer. The amplification products were analyzed by 1 % agarose gel electrophoresis (Wang et al. 2014; Mollasalehi and Yazdanparast 2013), and by NASBA-ELISA DIG detection system described below.

**Microtiter plate hybridization and detection of NASBA product**

Biotinylated probe (Hybridization probe) (0.1 mM, 100 μL) diluted in PBST buffer (phosphate-buffered saline containing 0.05 % (v/v) TWEEN-20, PH 7.2, prepared with DEPC water) was incubated in the streptavidin-coated microtiter plate (restored to room temperature from 4 °C, Haili, JiangSu, China) at room temperature for 1 h with gentle agitation. After aspiration, the plates were washed with 3 × 300 μL PBST buffer to prepare for assay application (Gill et al. 2006). For hybridization, 10 μL DIG-labeled NASBA product was heated 2 min at 95 °C to inactive Rnase H activity and mixed with 90 μL hybridization solution (50 mM sodium-phosphate buffer, pH 7.0, prepared with DEPC water). The mixture (100 μL) was added to the oligoprobe-coated streptavidin microtiter plate and incubated for 1 h at 37 °C with gentle shaking. The plates were washed with 3 × 300 μL PBST buffer. Anti-digoxigenin antibody ALP conjugate (Roche, Basel, Switzerland) diluted 500-fold in PBST buffer was added to each well in a final volume of 100 μL and the microtiter plates were incubated for 30 min at 37 °C. After five washes with PBST solution, 100 μL of developer PNPP (restored to room temperature from −20 °C, Yeasen, Shanghai, China) was added to each well and incubated in the dark at 37 °C for 15 min. Finally, 50 μL of stop solution was added and the developed color was measured at 405 nm in a microtiter plate reader (Ravan and Yazdanparast 2012; Gomes et al. 2010; Di Pinto et al. 2012). All experiments were performed in triplicate with negative controls, and data represent mean values. The cut-off value was calculated as the mean absorbance value of the negative controls plus three standard deviations, as obtained with a single NASBA-ELISA test. As the mean absorbance value and standard deviation were 0.059 ± 0.012, a sample was considered positive when the absorbance of the three measurements was greater than 0.095 (the cut-off value).

**Statistical analysis**

Performance parameters for each approach were analyzed by the MedCalc® 15.2.2 and SPSS22.0. Positive results from patients with proven or probable IA according to the EORTC/MSG criteria were considered to be true positives and used to calculate the sensitivity of the three assays. For calculation of specificity, negative results from patients without EORTC/MSG evidence of IA were considered to be true negatives. Receiver operating characteristic curve (ROC) was used to assess the diagnostic value of NASBA-ELISA system. A higher value of area under the curve (AUC) represents a greater diagnostic value of the assay. Comparison between two methods was performed by paired diagnosis test design using Fisher’s exact test to generate two-sided  P values with a  P value of ≤0.05 being considered significant. Absorbance readings and arithmetical means of the number of *Aspergillus* spores (transformed into log scale) were analyzed by Pearson’s parametric correlation coefficient or Spearman’s nonparametric correlation coefficient in the NASBA-ELISA test. The Youden index was calculated to evaluate the synthetic ability of each assay. A kappa statistic was determined and interpreted as described previously. Values greater than 0.8 means excellent agreement between methods, values of 0.61–0.8 means substantial agreement, values of 0.41–0.6 means moderate agreement, and values below 0.4 means poor agreement (White et al. 2013).

**Results**

**Analytical sensitivity of the NASBA process and analytical sensitivity of the NASBA-ELISA with DIG detection system**

Analytical sensitivity of NASBA by using 1 % agarose gel electrophoresis was obtained by 10-fold serial dilutions of genomic RNA (Fig. 1). The limit of detection was 1 CFU.

The efficiency of the NASBA-ELISA was proved by analyzing two fold serial dilutions of digoxigenin-labeled NASBA amplicons of *Aspergillus*. The OD increased with the increasing concentration of amplification products within a certain range (Fig. 2). Tenfold serial diluted concentrations of nucleic acid sample RNA extracted from a saline solution containing 10⁵ CFU *Aspergillus* spores were employed to determine the sensitivity of the developed method. As the OD₄₀₅ values for 1–10⁵ CFU were above the cut-off threshold value of 0.095 (Fig. 3), the lowest detection was 1 CFU, as the same as that obtained by 1 % agarose gel electrophoresis. The polynomial fitting between the optical density readings of
the NASBA-ELISA and the log number of the template spores was significant, with the determination coefficient of 0.986 (Fig. 4).

Analytical specificity of the NASBA-ELISA with DIG detection system

Experimental specificity was assessed by amplifying non-target RNA extracted from E. coli, C. albicans, C. neoformans, S. aureus and P. Aeruginosa. The amplification products were analyzed by ELISA. No positive results were demonstrated for these strains, indicating that the assay is highly specific for Aspergillus (Fig. 5).

Tests results of patients

The results of NASBA-ELISA, RT-PCR and GM-ELISA assays were listed in Table 2. The NASBA-ELISA OD values were assessed by ROC analysis (Fig. 6). Area under the curve = 0.760 (95 % CI 0.650–0.870). The diagnostic parameters were calculated for each method (Table 3). Comparison of the three assays revealed that NASBA-ELISA had the highest sensitivity, at 80.56 % (95 % CI 63.98–91.81), and RT-PCR had the highest specificity, at 84.00 % (95 % CI 70.89–92.83). Hypothesis testing revealed that sensitivity of NASBA-ELISA was significantly greater than that of GM-ELISA (P = 0.023) and
no other significant differences were observed among the three tests. In addition, the NASBA-ELISA assay had the best performance in negative predictive value, and Youden index, while RT-PCR was the best performing assay for positive likelihood ratio and positive predictive value. Optimal performance was achieved by comparing the performance of various combinations of the three tests (Table 4, the last page). Perfect specificity (100 %; 95 % CI 92.89–100) and perfect PPV (100 %; 95 % CI 83.16–100) were attainable by combining NASBA-ELISA with GM-EIA in serial testing. Combining NASBA-ELISA with RT-PCR appeared to be better than other combinations for sensitivity, NPV and Youden index.

Discussion

Invasive aspergillosis (IA) is recognized as an opportunistic infection among many categories of immunocompromised patients (Nabili et al. 2013) and continues to be problematic to diagnose due to the lack of rapid, specific, and sensitive diagnostic methods. The use of NASBA has been reported rarely to detect *Aspergillus* species (Dimopoulous et al. 2012). We developed an NASBA-ELISA assay for analyzing *Aspergillus* RNA in plasma sample to rapidly diagnose IA. ELISA techniques provide an alternative to gel electrophoresis for the detection of NASBA products.

Evaluation of the analytical sensitivity of the *Aspergillus* NASBA-ELISA system showed the same sensitive as NASBA-electrophoresis with the lowest detection concentration of 1 CFU. The high sensitivity of the method is due to two factors: (1) The target of NASBA-ELISA assay, 18s rRNA, is present at a level of approximately 100–300 copies in per fungal cell (Park et al. 2011); (2) The Biotin-Avidin-System (BAS) used for immobilization of amplification products on microtiter plates increases the sensitivity of procedure by taking advantage of its multi-stage amplification effect.

The NASBA-ELISA system was developed by using primers designed by Loeffler J et al. (2001), who proved specificity of the primers and the use of bioth-probe also assured fine specificity for *Aspergillus* genus. The specificity was also proved by the non-specific amplification signal when non-target RNA was used as templates in
our experiment. Further more, a potential risk of contamination with such non-target microbes nucleic acids could be ignored because only the target nucleic acids with T7 promoter can be amplified. Thus, the hybridization signals acquired were comparable in terms of intensity to that of Aspergillus alone. As the results indicated, the relation between optical density of ELISA and amplification products concentration was given through polynomial fitting. Once the ELISA reaction has reached saturation, the optical density maybe not be improved obviously by increasing concentration of products. Therefore, NASBA-ELISA assay can be taken as a semi-quantitative technique of amplification products analysis.

GM-ELISA is a broadly used routine diagnostic assay and has been enrolled as a formal component of diagnostic criteria in EORTC/MSG. Reverse transcriptase PCR (RT-PCR), involving treatment with reverse transcriptase enzyme (an RNA-dependent DNA polymerase) prior to a normal PCR, uses the same template RNA as NASBA. Thus, the diagnostic performance of the NASBA-ELISA was compared to RT-PCR and galactomannan (GM) by testing plasma samples simultaneously with the three methods.

It is known that GM testing frequently appeared false-positive results and low sensitivity for patients receiving preventive medication. A previous study has reported that GM is not released into the circulation during infection until the fungus invaded the endothelial compartment (Hope et al. 2007). This suggested that circulating GM could not be detected until angioinvasion by the fungus occurs. Antibodies to GM could also develop which have been suggested as a cause of false negative serum GM results in patients with IA (Herbrecht et al. 2002). It has also been reported that some false positive GM results derived from the existence of GM in some other fungi and in preparations of some antibiotic agents (Vergidis et al. 2012; Tortorano et al. 2012).

### Table 3 Performance parameters for GM ELISA, Aspergillus RT-PCR, and Aspergillus NASBA-ELISA when testing cases of proven/probable IA

| Parameter                        | NASBA-ELISA | RT-PCR | GM-ELISA |
|----------------------------------|-------------|--------|----------|
| Sensitivity [% (95 % CI)]        | 80.56 (63.98–91.81) | 72.22 (54.81–85.80) | 58.33 (40.76–74.49)* |
| Specificity [% (95 % CI)]        | 80.00 (66.28–89.97) | 84.00 (70.89–92.83) | 82.00 (68.56–91.42) |
| Positive likelihood ratio        | 2.26–7.17 | 2.32–8.79 | 1.69–6.23 |
| Negative likelihood ratio        | 0.12–0.48 | 0.19–0.57 | 0.34–0.76 |
| PPV [% (95 % CI)]                | 74.36 (57.87–86.96) | 76.47 (58.83–89.25) | 70.00 (50.60–85.27) |
| NPV [% (95 % CI)]                | 85.11 (71.69–92.80) | 80.77 (67.47–90.37) | 73.21 (59.70–84.17) |
| Youden index                     | 0.61       | 0.56   | 0.40     |
| κ statistic                      | 0.60       | 0.57   | 0.41     |

Combined analysis for both proven IA (n = 9) and probable IA (n = 27)
Best performance values are highlighted in italics
* P < 0.05 versus NASBA-ELISA

### Table 4 Combined assay performance for GM ELISA, Aspergillus RT-PCR, and Aspergillus NASBA-ELISA when testing cases of proven/probable IA

| Parameter                        | NASBA-ELISA or RT-PCR | NASBA-ELISA and RT-PCR | NASBA-ELISA or GM-ELISA | NASBA-ELISA and GM-ELISA | RT-PCR or GM-ELISA | RT-PCR and GM-ELISA |
|----------------------------------|------------------------|------------------------|-------------------------|--------------------------|------------------------|---------------------|
| Sensitivity [% (95 % CI)]        | 97.22 (85.47–99.93)   | 55.56 (38.10–72.06)   | 83.33 (67.19–93.63)   | 55.56 (38.10–72.06)   | 77.78 (60.85–89.88) | 52.78 (35.49–69.59) |
| Specificity [% (95 % CI)]        | 68.00 (53.30–80.48)   | 94.00 (83.45–98.75)   | 62.00 (47.17–75.35)   | 100 (92.89–100)       | 66.00 (51.23–78.79) | 98.00 (89.35–99.95) |
| Positive likelihood ratio        | 3.04 (2.02–4.57)      | 9.26 (2.98–28.82)     | 2.19 (1.50–3.22)      | Infinity               | 2.29 (1.50–3.49)    | 26.39 (3.70–188.24) |
| Negative likelihood ratio        | 0.04 (0.01–0.28)      | 0.47 (0.33–0.69)      | 0.27 (0.13–0.58)      | 0.44 (0.31–0.64)      | 0.34 (0.18–0.64)    | 0.48 (0.34–0.68)    |
| PPV [% (95 % CI)]                | 68.63 (54.11–80.89)   | 86.96 (66.41–97.22)   | 61.22 (46.24–74.80)   | 100 (83.16–100)       | 62.22 (46.54–76.23) | 95.00 (75.13–99.87) |
| NPV [% (95 % CI)]                | 97.14 (85.08–99.93)   | 74.60 (62.06–84.73)   | 83.78 (67.99–93.81)   | 75.76 (63.64–85.46)   | 80.49 (65.13–91.18) | 74.24 (61.99–84.22) |
| Youden index                     | 0.652                 | 0.496                 | 0.453                  | 0.556                   | 0.438                  | 0.508                |

Combined analysis for both proven IA (n = 9) and probable IA (n = 27)
Best performance values are highlighted in italics
* “or” indicates that at least one of the assays is required to be positive
b “and” indicates that both assays are required to be positive before a patient is considered positive
The RT-PCR had the best performance in specificity, Positive likelihood ratio and positive predictive value in our present findings. However, it has lower sensitivity compared with NASBA-ELISA, indicating that the amplification efficiency of PCR is lower than NASBA as they all using the same RNA template. Lacking of standardization of PCR led to the failure to include DNA detection being incorporated into the EORTC/MSG criteria for the definition of invasive fungal infection.

The NASBA-ELISA was proved the most sensitive assay and had the best performance in negative predictive value, Youden index, and K value in our present findings. The high sensitivity of NASBA-ELISA is probably since that NASBA possesses a higher inherent amplification capability than RT-PCR because each cDNA template produces numerous RNA copies per cycle in the former technique while each cDNA merely doubles in number at each cycle in the latter. Further more, the detection procedure is conducted with enzyme-linked immunosorbent assay of DIG-labeled NASBA amplicons. NASBA is better to reveal IA infection status since the RNA template of NASBA amplification is closely related to active microbes. Since the NASBA assay only allows amplification of template nucleic acids with T7 promoter and thermal denaturation is absent for NASBA, contaminating background of homologous DNA is not a problem. As an alternative technology to detect NASBA amplification products, ELISAs avoid subjective interpretations of amplification results due to “bands of unknown origin” or “nonspecific products” among other features and can detect batch of samples automatically. Moreover, though NASBA-ELISA is a technique of end-point amplification products analysis, it also allows for quantification in a certain range of original RNA concentrations that cover all the significant amount of Aspergillus in clinical samples.

In this study, we developed a simple quantitative microplate hybridization method for detection of NASBA products and evaluated its performance by plasma sample of patients at high risk for IA. The results exhibited that NASBA-ELISA has several advantages such as high sensitivity, good specificity (absence of cross-reactivity with other unrelated bacteria or fungus) and can be easily performed. It can analyze a numbers of samples simultaneously without any special instrument and reasonably it may be particularly useful for routine purposes in less developed laboratories. Combining NASBA-ELISA with other techniques can improve the diagnostic accuracy and could be particularly useful in specific clinical situations.

### Abbreviations

NASBA-ELSA: enzyme-linked immunosorbent assay of nucleic acid sequence-based amplification; IA: invasive aspergillosis; GM: galactomannan; GM-ELISA: galactomannan by enzyme immunosorbent assay; E.coli: Escherichia coli; C. albicans; Candida albicans; S. aureus: Staphylococcus aureus; P. aeruginosa: Pseudomonas aeruginosa; C.neoforans: Cryptococcus neoformans.

### Authors’ contributions

LD performed the NASBA-ELISA, all of data analysis and wrote the manuscript. YX designed the study and supervised all the experiments. YH corrected the manuscript. QP, RH, WW performed RT-PCR, GM-ELISA and data collection, respectively. All authors read and approved the final manuscript.

## Acknowledgements

We thank Dr. Weiping Lu from Daping Hospital of Third Military Medical University in China for sending us the A. fumigatus strain of CMCC A1a that were used in this study.

Funding was provided by “the Project of Scientific Research of Chongqing Public Health Bureau” (2008-2-312), “the Project of National Clinical Key-discipline Construction” (2010 (305)) and “the Fundamental and Front Research Funds of Chongqing” (20160129).

### Competing interests

The authors declare that they have no competing interests.

### Ethical approval

This article is a retrospective anonymous performance evaluation using excess clinical samples with no impact on patient management not requiring ethical approval.

Received: 22 July 2016 Accepted: 29 September 2016
Published online: 06 October 2016

### References

Barton Richard C (2013) Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo). doi:10.1155/2013/459405

Boutboul F, Albert C, Leblanc T, Sualhian A, Gluckman E, Derouin F, Ribaud P (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 34:939–943. doi:10.1086/339324

Chandrakeer R (2010) Diagnostic challenges and recent advances in the early management of invasive fungal infections. Eur J Haematol 84(4):281–290. doi:10.1111/j.1600-0609.2009.01393.x

De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Mastrageloy G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kulberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821. doi:10.1086/588660

Di Pinto A, Terio V, Di Pinto P, Colao V, Tantillo G (2012) Detection of Vibrio parahaemolyticus in shellfish using polymerase chain reaction-enzyme-linked immunosorbent assay. Lett Appl Microbiol 54(6):494–498. doi:10.1111/j.1472-765X.2012.03231.x

Dimopoulos G, Frantzeskaki F, Poulakou G, Armaganidis A (2012) Invasive aspergillosis in the intensive care unit. Ann NY Acad Sci 1272:31–39. doi:10.1111/j.1749-6632.2012.06805.x

### Additional file

**Additional file 1.** Additional table.
Park C, Kwon EY, Shin NY, Choi SM, Kim SH, Park SH, Lee DG, Choi JH, Yoo JH (2011) Evaluation of nucleic acid sequence based amplification using fluorescence resonance energy transfer (FRET-NASBA) in quantitative detection of Aspergillus 18S rRNA. Med Mycol 49(1):73–79. doi:10.1099/693786.2010.507604

Ravan H, Yazdanparast R (2012) Development and evaluation of a loop-mediated isothermal amplification method in conjunction with an enzyme-linked immuno-sorbent assay for specific detection of Salmonella serogroup D. Anal Chim Acta 733:64–70. doi:10.1016/j.aca.2012.04.034

Torelli R, Sanguinetti M, Woody A, Pagano L, Caira M, De Catolico E, Fuso L, De Pascale G, Bello G, Antonelli M, Fadda G, Posterao B (2011) Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol 49:4273–4278. doi:10.1128/JCM.05266-11

Tortorano AM, Esposto MC, Prittigato A, Giancini A, Ossi C, Cavanna C, Cacio GL (2012) Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan-enzyme-linked immunosorbent assay. J Clin Microbiol 50(3):1051–1053. doi:10.1128/JCM.00946-11

van der Vliet GM, Schukkink RAF, van Gemen B, Schepers P, Klatser PR (1993) Nucleic acid sequence-based amplification (NASBA) for the identification of mycobacteria. J Gen Microbiol 139:2423–2429. doi:10.1099/6022187-37-10-2423

Vergidis P, Walker RC, Kaul DR, Kaufman CA, Freifeld AG, Slagle DC, Kresse AB, Wheat LJ (2012) False-positive Aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis. Transpl Infect Dis 14(2):213–217. doi:10.1111/j.1399-3062.2011.00675.x

Wang L, He Y, Xia Y, Su X, Wang H, Liang S (2014) Retrospective comparison of nucleic acid sequence-based amplification, real-time PCR, and galactomannan test for diagnosis of invasive aspergillosis. J Mol Diagn 16(5):584–590. doi:10.1016/j.jmoldx.2014.05.001

White PL, Parr C, Thornton C, Barnes RA (2013) Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 51(5):1510–1516. doi:10.1128/JCM.03189-12

Yoo JH, Choi SM, Lee DG, Park SH, Choi JH, Kwon EY, Shin WS (2007) Comparison of the real-time nucleic acid sequence-based amplification (RTi-NASBA) with conventional NASBA, and galactomannan assay for the diagnosis of invasive aspergillosis. J Korean Med Sci 22:672–676. doi:10.3346/jkms.2007.22.4.672

Zhou Y, Park S, Kreiswirth BN, Ginocchio CC, Veyret R, Laayouna A, Trosch A, Perlin DS (2009) Rapid real-time nucleic acid sequence-based amplification molecular beacon platform to detect fungal and bacterial bloodstream infections. J Clin Microbiol 47:2067–2078. doi:10.1128/JCM.02230-08